|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肝细胞焦亡和炎性小体颗粒释放诱发肝星状细胞活化和肝纤维化显示文摘【据Journal of Hepatology 2020年8月报道】肝细胞焦亡和炎性小体颗粒释放诱发肝星状细胞活化和肝纤维化(作者Gaul S等)肝细胞死亡增加导致急性和慢性肝病的病理改变。肝细胞焦亡和细胞外炎性小体释放在肝病中的作用尚不清楚。来自美国圣地牙哥加利福尼亚大学儿科部的Gaul等使用原代小鼠和人肝细胞、肝细胞特异性L351P Nlrp3 KI CreA小鼠和Gsdmd KO小鼠研究肝细胞焦亡及其对肝脏炎症和损伤的影响。从突变型NLRP3-yfp HEK细胞中分离到细胞外NLRP3炎性体,并在LX2和原代人肝星状细胞中研究内化。进一步使用了154例经活检证实的NAFLD成人受试者的肝细胞(西澳大利亚奈德兰兹查尔斯·盖德纳爵士医院)。 | 李杰 牛俊奇 GAUL S LESZCZYNSKA A ALEGRE F | 2020 | 临床肝胆病杂志2020，36，10： | 26 |
| 2 | Using old liver grafts for liver transplantation: Where are the limits?显示文摘The scarcity of ideal liver grafts for orthotopic liver transplantation(OLT) has led transplant teams to investigate other sources of grafts in order to augment the donor liver pool. One way to get more liver grafts is to use marginal donors, a not well-defined group which includes mainly donors > 60 years, donors with hypernatremia or macrosteatosis > 30%, donors with hepatitis C virus or hepatitis B virus positive serologies, cold ischemia time > 12 h, non-heart-beating donors, and grafts from split-livers or living-related donations. Perhaps the most practical and frequent measure to increase the liver pool, and thus to reduce waiting list mortality, is to use older livers. In the past years the results of OLT with old livers have improved, mainly due to better selection and maintenance of donors, improvements in surgical techniques in donors and recipients, and intra- and post-OLT management. At the present time, sexagenarian livers are generally accepted, but there still exists some controversy regarding the use of septuagenarian and octogenarian liver grafts. The aim of this paper is to briefly review the aging process of the liver and reported experiences using old livers for OLT. Fundamentally, the series of septuagenarian and octogenarian livers will be addressed to see if there is a limit to using these aged grafts. | Carlos Jiménez-Romero Oscar Caso Maestro Félix Cambra Molero Iago Justo Alonso Cristina Alegre Torrado Alejandro Manrique Municio Jorge Calvo Pulido Carmelo Loinaz Segurola Enrique Moreno González | 2014 | World Journal of Gastroenterology2014，20，31： | 11 |
| 3 | Vitreous amyloidosis without systemic or familial involvement显示文摘 | Salvador F Mateo C Alegre J | 1994 | Int Ophthalmol 1993-1994，17，6： | 1 |
| 4 | Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease 显示文摘 | Alonso - Frech F Zamarbide I Alegre M | 2006 | Brain2006，129，7： | 1 |
| 5 | How relevantare flavonoids as antioxidant in plants 显示文摘 | Hernandez I Alegre L Van Breusegem F | 2009 | Trends Plant Sci2009，14，： | 1 |
| 6 | Differ- ences in surface marker expression and chondrogenic potential a- mong various tissue - derived mesenchymal cells from elderly pa- tients with osteoarthritis 显示文摘 | Alegre - Aguar6n E Desportes P Garcta - lvarez F | 2012 | Ceils Tissues Organs2012，196，3： | 1 |
| 7 | 利匹韦林通过选择性STAT1介导的肝星状细胞凋亡改善肝纤维化显示文摘【据《Gut》2019年9月报道】题:利匹韦林通过选择性STAT1介导的肝星状细胞凋亡改善肝纤维化(作者Martí-Rodrigo A等)。肝纤维化发病率逐年上升,缺乏具体有效的治疗措施,已经成为一个重大的公共卫生问题。大量研究结果表明,机体主要通过细胞因子激活JAK-STAT通路来调节肝纤维化和肝细胞再生。利匹韦林是一种临床上广泛应用的抗HIV药物,目前尚无肝毒性报道。本研究中,来自西班牙瓦伦西亚大学大学医学院药理学系的Martí-Rodrigo等主要研究了利匹韦林在几种慢性肝损伤模型中的肝脏保护作用,并研究了其作用机制:JAK-STAT信号调节。研究人员利用营养性非酒精性脂肪肝、四氯化碳致肝纤维化和胆管结扎致肝纤维化三种小鼠模型,研究了利匹韦林对肝脂肪变性、炎症和纤维化的影响。并利用原代人肝星状细胞,人肝细胞株lx-2、hep3b研究了其潜在的分子机制。 | 任天棋 杨倩倩 乔天一 牛俊奇 MART■-RODRIGO A ALEGRE F MORAGREGA ■B | 2020 | 临床肝胆病杂志2020，36，1： | 1 |
| 8 | Mechanisms of CTLA-4-Ig in tolerance induction显示文摘 | Alegre ML Fallarino F | 2006 | Curr Pharm Des2006，12，2： | 1 |
| 9 | How relevant are flavonoids as antioxidants in plants? 显示文摘 | Herndndez I Alegre L Van Breusegem F | 2009 | Trends Plant Sci2009，14，： | 1 |
| 10 | Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease显示文摘 | Alonso-Frech F Zamarbide I Alegre M | 2006 | Brain2006，129，7： | 1 |
| 11 | Evaluation of environmental management resources (ISO14001) at civil engineering construction worksites: A case study of the community of Madrid 显示文摘 | Rodriguez G Alegre F J Martinez G | 2011 | Journal of Environmental Management2011，92，： | 1 |
| 12 | Mechanisms of CTLA-4-Ig in Tolerance Induction显示文摘 | ALEGRE ML FALLARINO F | 2006 | Curr Pharm Des(S1381-6128)2006，12，2： | 1 |
| 13 | Mechanisms of CTLA - 4 - Ig in tolerance induction 显示文摘 | Alegre M L Fallarino F | 2006 | Curr Pharm Des2006，12，2： | 1 |
| 14 | Mechanisms of CTLA-4-Ig in tolerance induction显示文摘 | Alegre ML Fallarino F | 2006 | Curt Pharm Des2006，12，2： | 1 |
| 15 | Mechanisms of CTLA4-Ig in tolerance induction显示文摘 | Alegre M L Fallarino F | 2006 | Curr Pharm Des2006，12，2： | 1 |
| 16 | Mechanisms of CTLA -4 -Ig in tolerance induction 显示文摘 | Alegre M L Fallarino F | 2006 | Curr Pharm Des2006，12，2： | 1 |
| 17 | ERstress in human hepatic cells treated with Efavirenz : mi-tochondria again 显示文摘 | Apostolova N Gomez-Sucerquia U Alegre F | 2013 | J Hepatol2013，59，4： | 1 |
| 18 | Virology, epidemiology and transmission mechanisms of hepatitis B virus 显示文摘 | Moreno D Alegre F Garcia-Gonzalez N | 2004 | An Sist Sanit Nayar2004，27，2： | 1 |
| 19 | Henoch-Schnlein purpura associated with celiac disease显示文摘 | Landecho MF Ros NF Alegre F | 2011 | J Am Acad Dermatol2011，64，6： | 1 |
| 20 | Smart Oil Recovery 显示文摘 | Da Rocha Armando F Morooka Celso K Alegre Lideniro | 1996 | IEEE Spectrum1996，33，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员